Methods and dressings for sealing internal injuries
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61B-017/03
A61L-015/00
A61B-017/00
출원번호
US-0080086
(2011-04-05)
등록번호
US-9131929
(2015-09-15)
발명자
/ 주소
MacPhee, Martin
Kanellos, Jerry
Wilmer, Belinda
Beall, Dawson
출원인 / 주소
STB, Ltd.
대리인 / 주소
Vivicar Law, PLLC
인용정보
피인용 횟수 :
2인용 특허 :
80
초록
Disclosed are solid and frozen haemostatic materials and dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings.
대표청구항▼
1. A device for treating wounded internal tissue in a mammal comprising: (a) an applicator; and(b) a haemostatically effective amount of a casted haemostatic material, wherein said casted haemostatic material consisting essentially of a substantially homogeneous mixture of a fibrinogen component and
1. A device for treating wounded internal tissue in a mammal comprising: (a) an applicator; and(b) a haemostatically effective amount of a casted haemostatic material, wherein said casted haemostatic material consisting essentially of a substantially homogeneous mixture of a fibrinogen component and a fibrinogen activator, wherein said fibrinogen component is present in an amount between 26 to about 450 mg per square centimeter of the surface intended to contact the wounded internal tissue being treated and wherein the fibrinogen activator is employed between about 0.0087-1.000 mg fibrinogen component, and wherein said fibrinogen component and fibrinogen activator are cooled to about 4° C.+/−2° C. before casting. 2. The device of claim 1, wherein said applicator comprises a plunger or tamper. 3. The device of claim 1, wherein said applicator comprises a guide wire. 4. The device of claim 1, wherein said haemostatic material includes at least one support layer. 5. The device of claim 4, wherein said support layer comprises a backing material. 6. The device of claim 4, wherein said support layer comprises an internal support material. 7. The device of claim 4, wherein said support layer comprises a resorbable material. 8. The device of claim 4, wherein said support layer comprises a non-resorbable material. 9. The device of claim 8, wherein said non-resorbable material is selected from the group consisting of silicone polymers, paper, gauze, plastics, non-resorbable suture materials, and latexes. 10. The device of claim 4, further comprising at least one physiologically acceptable adhesive between said haemostatic material and said support layer. 11. The device of claim 7, wherein said resorbable material is selected from the group consisting of proteinaceous materials, carbohydrate substances and resorbable suture materials. 12. The device of claim 11, wherein said proteinaceous material is at least one substance selected from the group consisting of keratin, silk, fibrin, collagen, and gelatin. 13. The device of claim 11, wherein said carbohydrate substance is selected from the group consisting of alginic acid and salts thereof, chitin, chitosan, cellulose, n-acetyl glucosamine, proteoglycans, glycolic acid polymers, lactic acid polymers, glycolic acid/lactic acid co-polymers, and mixtures of two or more thereof. 14. The device of claim 1, wherein said haemostatic material also contains a fibrin crosslinker and/or a source of calcium ions. 15. The device of claim 1, wherein said haemostatic material also contains one or more of the following: at least one filler; at least one solubilizing agent; at least one foaming agent; and at least one release agent. 16. The device of claim 15, wherein said filler is selected from the group consisting of sucrose, lactose, maltose, keratin, silk, fibrin, collagen, gelatin, albumin, polysorbate, chitin, chitosan, alginic acid and salts thereof, cellulose, proteoglycans, glycolic acid polymers, lactic acid polymers, glycolic acid/lactic acid co-polymers, and mixtures of two or more thereof. 17. The device of claim 15, wherein said solubilizing agent is selected from the group consisting of sucrose, lactose, maltose, dextrose, mannose, trehalose, mannitol, sorbitol, albumin, sorbate, polysorbate, and mixtures of two or more thereof. 18. The device of claim 15, wherein said release agent is selected from the group consisting of gelatin, mannitol, sorbitol, polysorbate, sorbitan, lactose, maltose, trehalose, sorbate, glucose and mixtures of two or more thereof. 19. The device of claim 15, wherein said foaming agent is selected from the group consisting of mixtures of sodium bicarbonate/citric acid, sodium bicarbonate/acetic acid, calcium carbonate/citric acid and calcium carbonate/acetic acid. 20. The device of claim 1, wherein said haemostatic material also contains at least one therapeutic supplement selected from the group consisting of antibiotics, anticoagulants, steroids, cardiovascular drugs, growth factors, antibodies (poly and mono), chemoattractants, anesthetics, antiproliferatives/antitumor agents, antivirals, cytokines, colony stimulating factors, antifungals, antiparasitics, antiinflammatories, antiseptics, hormones, vitamins, glycoproteins, fibronectin, peptides, proteins, carbohydrates, proteoglycans, antiangiogenins, antigens, nucleotides, lipids, liposomes, fibrinolysis inhibitors, procoagulants, anticoagulants, vascular constrictors and gene therapy reagents. 21. The device of claim 20, wherein said therapeutic supplement is present in an amount equal to or greater than its solubility limit in fibrin. 22. The device of claim 1, wherein said haemostatic material further contains at least one binding agent in an amount effective to retain the physical integrity of said haemostatic material. 23. The device of claim 22, wherein said binding agent is selected from the group consisting of sucrose, mannitol, sorbitol, gelatin, maltose, povidone, chitosan, carb oxymethylcellulose and derivatives thereof. 24. The device of claim 1, wherein said haemostatic material has been subjected to at least one process selected from the group consisting of lyophilization, drying, spray-drying, vacuum drying and vitrification, and combinations of two or more thereof. 25. The device of claim 1, wherein said haemostatic material has moisture content of at least 6%. 26. The device of claim 1, wherein said haemostatic material has moisture content of less than 6%. 27. The device of claim 1, wherein said haemostatic material is frozen. 28. The device of claim 1, wherein said fibrinogen component is a mammalian fibrinogen. 29. The device of claim 28, wherein said mammalian fibrinogen is selected from the group consisting of bovine fibrinogen, porcine fibrinogen, ovine fibrinogen, equine fibrinogen, caprine fibrinogen, feline fibrinogen, canine fibrinogen, murine fibrinogen and human fibrinogen. 30. The device of claim 1, wherein said fibrinogen component is selected from the group consisting of bird fibrinogen and fish fibrinogen. 31. The device of claim 1, wherein said fibrinogen component is selected from the group consisting of human fibrinogen, human fibrin I, human fibrin II, human fibrinogen a chain, human fibrinogen β chain, human fibrinogen γ chain, and mixtures of two or more thereof. 32. The device of claim 28, wherein said mammalian fibrinogen is recombinantly produced fibrinogen. 33. The device of claim 1, wherein said fibrinogen activator is selected from the group consisting of thrombins, prothrombins, snake venoms, and mixtures of any two or more thereof. 34. The device of claim 33, wherein said thrombin is mammalian thrombin. 35. The device of claim 34, wherein said mammalian thrombin is selected from the group consisting of bovine thrombin, porcine thrombin, ovine thrombin, equine thrombin, caprine thrombin, feline thrombin, canine thrombin, murine thrombin and human thrombin. 36. The device of claim 33, wherein said thrombin is selected from the group consisting of bird thrombin and fish thrombin. 37. The device of claim 34 or 36, wherein said thrombin is recombinantly produced thrombin. 38. The device of claim 2, wherein said applicator further comprises a sheath or barrel.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (80)
Redl Heinz (Vienna ATX) Habison Georg (Vienna ATX), Apparatus for applying a tissue adhesive.
Redl Heinz (Vienna ATX) Schlag Gnther (Vienna ATX) Pridun Nestor (Vienna ATX), Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation.
Drohan William N. ; MacPhee Martin J. ; Miekka Shirley I. ; Singh Manish S. ; Elson Clive,CAX ; Taylor ; Jr. John R., Chitin hydrogels, methods of their production and use.
Errede Louis A. (North Oaks MN) Stoesz James D. (St. Paul MN) Winter ; deceased George D. (late of St. Paul MN by Jenny Upton ; personal representative), Composite wound dressing.
Brown Ross G. (Terre Haute IN) Bright David R. (Terre Haute IN) Williams Robert D. (Terre Haute IN), Fibrin binder/carrier for active biochemical agents.
Wahlig Helmut (Darmstadt DEX) Dingeldein Elvira (Dreieich DEX) Kirchlechner Richard (Rott a. Inn DEX) Orth Dieter (Darmstadt DEX) Rogalski Werner (Alsbach DEX), Flavonoid phosphate salts of aminoglycoside antibiotics.
Ron Eyal (Lexington MA) Schaub Robert G. (Pelham NH) Turek Thomas J. (Boston MA), Formulations of blood clot-polymer matrix for delivery of osteogenic proteins.
Nesburn Anthony B. (Malibu CA) Gorin Michael (Rockville MD) Martinez Marvin (Glendale CA) Kenney M. Cristina (Malibu CA) Maguen Ezra (Los Angeles CA), Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers.
Nesburn Anthony B. (Malibu CA) Gorin Michael (Rockville MD) Martinez Marvin (Glendale CA) Kenney M. Cristina (Malibu CA) Maguen Ezra (Los Angeles CA), Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers.
Nesburn Anthony B. (Malibu CA) Gorin Michael (Rockville MD) Martinez Marvin (Glendale CA) Kenney M. Cristina (Malibu CA) Maguen Ezra (Los Angeles CA), Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers.
Williams Stuart K. (Drexel Hill PA) Jarrell Bruce E. (Philadelphia PA), Method of treating a synthetic or naturally occuring surface with microvascular endothelial cells, and the treated surfa.
Edwardson Peter A. D.,GBX ; Fairbrother John E.,GBX ; Gardner Ronald S.,GBX ; Hollingsbee Derek A.,GBX ; Cederholm-Williams Stewart A.,GBX, Nondynamic fibrin monomer on bandages, sutures, prostheses and dressings.
Zimmermann Eberhard (Am Braaken 16 4400 Mnster-Nienberge DEX) Stroetmann Michael (Kaiser-Wilhelm-Ring 36 4400 Mnster DEX), Resorptive sheet material for closing and healing wounds and method of making the same.
Zimmermann Eberhard (Mnster-Nienberge DEX) Stroetmann Michael (Mnster DEX), Resorptive sheet material for closing and healing wounds and method of making the same.
MacPhee Martin James ; Drohan William Nash ; Liau Gene ; Haudenschild Christian, Supplemented and unsupplemented tissue sealants, method of their production and use.
Drohan,William N.; MacPhee,Martin J.; Burgess,Wilson H.; Nunez,Hernan; Singh,Manish; Liau,Gene; Maciag,Thomas, Supplemented and unsupplemented tissue sealants, methods of their production and use.
MacPhee Martin James ; Drohan William Nash ; Lasa ; Jr. Carlos I.,PHX ; Liau Gene ; Haudenschild Christian, Supplemented and unsupplemented tissue sealants, methods of their production and use.
MacPhee Martin James ; Drohan William Nash ; Woolverton Christoper J., Supplemented and unsupplemented tissue sealants, methods of their production and use.
Tse Daphne C. ; Mankarious Samia S. ; Liu Shu Len ; Thomas William R. ; Alpern Melaine ; Enomoto Stanley T. ; Garanchon Cataline M., Topical fibrinogen complex.
Luck Edward E. (Menlo Park CA) Brown Dennis M. (Menlo Park CA), Treatments employing drug-containing matrices for introduction into cellular lesion areas.
Luck Edward E. (Menlo Park CA) Brown Dennis M. (Menlo Park CA), Treatments employing drug-containing matrices for introduction into cellular lesion areas.
Antoniades Harry N. (Newton MA) Lynch Samuel E. (Jamaica Plain MA) Williams Ray C. (Arlington MA), Wound healing and bone regeneration using PDGF and IGF-I.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.